LIVN LivaNova PLC logo

LIVN LivaNova PLC

Healthcare
$73.83+0.26%ClosedMarket Cap: $4.06B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

3.33

P/S

2.83

EV/EBITDA

16.53

DCF Value

$-14.20

FCF Yield

4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

67.6%

Operating Margin

14.2%

Net Margin

7.5%

ROE

9.1%

ROA

4.3%

ROIC

10.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$362.3M$22.3M$
Q4 null$360.9M$30.9M$
FY null$1.39B$-242.5M$
Q3 null$357.8M$26.8M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$79.25

Target (Median)

$80.50

Target Range

$66.00 - $90.00

2 Strong Buy6 Buy3 Hold0 Sell0 Strong Sell
BairdOutperform
2026-05-07
MizuhoOutperform
2026-05-07
BarclaysEqual Weight
2026-05-07
BarclaysEqual Weight
2026-02-27
NeedhamBuy
2026-02-25

Trading Activity

Insider Trades

View All
Tezel Ahmetofficer: Chief Innovation Officer
SellWed Apr 01
Tezel Ahmetofficer: Chief Innovation Officer
SellWed Apr 01
Tezel Ahmetofficer: Chief Innovation Officer
SellWed Apr 01
Tezel Ahmetofficer: Chief Innovation Officer
SellWed Apr 01
Poletti Francoofficer: President, Cardiopulmonary
SellWed Apr 01

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

GB

Exchange

Beta

0.82

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Peers